Bedtime cimetidine maintenance treatment: optimum dose and effect on subsequent natural history of duodenal ulcer*

W J F FITZPATRICK, W S BLACKWOOD, AND T C NORTHFIELD

From the Norman Tanner Gastroenterology Unit, St. James’s Hospital, and Department of Medicine, St. George’s Hospital Medical School, London

SUMMARY  Sixty patients, whose duodenal ulcers had healed endoscopically after six weeks of treatment with cimetidine 1g/day in divided doses, were treated with maintenance cimetidine 800 mg at bedtime for six months. Eighteen relapsed endoscopically (30%). Of the 42 still in remission, 36 then completed a six month double-blind comparison of bedtime cimetidine 400 mg and placebo. Twelve of the 19 (63%) cimetidine-treated patients and 10 of 17 (59%) placebo-treated patients relapsed within six weeks (NS). This high relapse rate on cimetidine contrasts with our earlier trial, in which the six week relapse rate was only two out of 21 (10%) on bedtime cimetidine 800 mg and 16 out of 24 (66%) on placebo (p < 0.0005). Apart from the difference in the dose of cimetidine, both our trials used the same experimental protocol during the double-blind part of the trial. In the earlier trial, however, there was no period of pretreatment with maintenance cimetidine as in the present trial. The pattern of placebo relapse was similar in both trials. We conclude that bedtime cimetidine maintenance treatment does not alter the long-term natural history of duodenal ulcer once it has been withdrawn; and that either tolerance to cimetidine develops during long-term maintenance treatment, or that bedtime cimetidine maintenance treatment in the conventional dose of 400 mg is not as effective as 800 mg in prevention of endoscopic relapse, although it does reduce symptoms.

The histamine H₂ receptor antagonist cimetidine promotes duodenal ulcer healing.¹ ² Maintenance therapy reduces the relapse rate in patients receiving the recommended dose of 400 mg at bedtime, but clinical trials have been mainly based on symptomatic relapse, with subsequent endoscopic confirmation. Additional endoscopies have been carried out at regular intervals in only a minority of trials,³ ⁴ and even then at infrequent intervals, usually once every six months,⁵ ⁶ which may not be adequate to provide reliable figures for asymptomatic relapse. Thus, it is not clear whether the main effect of cimetidine maintenance treatment 400 mg at bedtime is due to prevention of duodenal ulcer recurrence, or to prevention of symptoms (antacid effect) once the ulcer has recurred. If the latter were the main effect, this might account for the finding that there is a progressive increase in symptomatic relapse rate with time, reported as 2% per month in combined figures from many centres.⁷

Duodenal ulcer is a self-limiting disease, with a strong tendency to go into spontaneous remission after a variable number of years.⁸ Thus, no relapse might follow a period of maintenance treatment in those due to go into spontaneous remission during this time. On the other hand, spontaneous remission might be due to some protective mechanism, suppressed by maintenance treatment with cimetidine, in which case cessation of treatment might be followed by an increased relapse rate or 'rebound phenomenon'. The latter possibility is raised by the many anecdotal reports of perforated duodenal ulcer, acute gastrointestinal bleeding, and severe ulcer pain shortly after stopping cimetidine; by the finding that the relapse rate is higher in patients whose duodenal ulcers have healed on cimetidine treatment than in those who have healed on placebo;⁹ and by the report that relapse is more common after stopping treatment

* This study was presented at the annual meeting of the British Society of Gastroenterology, 1979.

† Present address: Merrimack Medical Park, Merrimack, New Hampshire 03054, USA.

Received for publication 10 September 1981
with cimetidine than after stopping treatment with tri-
potassium dicitrato bismuthate. On the other hand,
several studies have emphasised the frequency with
which the symptoms of duodenal ulcer recur after stop-
ping cimetidine maintenance treatment. In some, but not all, of these reports symptomatic relapse has
been confirmed by subsequent endoscopy. In none of
these studies have endoscopies, the only truly objective method of studying the effect of cimetidine main-
tenance treatment on the subsequent natural history of
duodenal ulcer, been carried out at regular intervals in
asymptomatic patients.

In the current study, endoscopy was carried out at
regular intervals in order to determine (1) whether
bedtime cimetidine maintenance treatment in the
currently recommended dose of 400 mg reduces the
endoscopic relapse rate of duodenal ulcer by compar-
ison with placebo. The design of this study was identical
with that of our previous double-blind comparison of
bedtime cimetidine 800 mg with placebo; (2) whether
six months' maintenance treatment with cimetidine
alters the subsequent natural history of duodenal ulcer,
as assessed by regular endoscopies after substitution of
placebo maintenance treatment on a double-blind basis.

Methods

PATIENTS

All the patients had active duodenal ulceration con-
"formed on endoscopy. They were treated with cimet-
dine 1 g daily in divided doses for six weeks, then within
one week of endoscopic confirmation of ulcer healing
(defined as complete disappearance of all breaks in
mucosal surface, however small or superficial) they
were started on cimetidine 800 mg at bedtime. After six
months' open treatment repeat endoscopy was carried
out. Patients having no endoscopic relapse of their du-
odenal ulcer at this stage were then randomly allocated to
bedtime cimetidine in a lower dose of 400 mg or to
placebo. Repeat endoscopy was carried out at six, 12,
and 24 weeks after randomisation. In our earlier
study, a double-blind comparison was made between
placebo and cimetidine 800 mg at bedtime with repeat
endoscopies carried out at the same time intervals. In
both trials, endoscopic relapse was defined as reappearance of any break in the continuity of the duodenal
mucosa however small. Recurrence of ulcer pain was
recorded on diary cards.

The χ² test (with correction for small numbers) was
used to compare the frequency of ulcer relapse. The
Wilcoxon rank sum test was used to compare the num-
ber of days and nights of pain and antacid consumption
on placebo and cimetidine.

Results

ENDOSCOPIC RELAPSE RATE

In the open part of our trial, 60 patients received cime-
tidine in a dose of 800 mg at bedtime for six months.
Repeat endoscopy at six months showed that 18 of the
60 patients had relapsed (30%). This is a similar relapse
rate (24%) to that obtained in our previous trial when
five out of 21 relapsed on the same dose of cimetidine,
thus confirming the consistency of our endoscopic
criteria.

After the open part of the trial, 40 of 42 patients still
in endoscopic remission entered the double-blind sec-
tion with either cimetidine 400 mg or placebo at bed-
time. Four failed to complete the six month trial
because of the repeated endoscopies involved. Nineteen
cimetidine-treated patients and 17 placebo-treated
patients completed the trial with endoscopic relapse
occurring in 14 and 11 patients respectively (NS). The
results for the trial are shown in the Table, which gives
the cumulative relapse rate at six, 12, and 24 weeks
after randomisation and compares these with our pre-
vious study. In contrast with our first study, bedtime
cimetidine in the lower dose of 400 mg did not reduce
the endoscopic relapse rate significantly; whereas the
placebo relapse rates in both trials were similar.
This difference in the cimetidine results between our
two trials was statistically significant at six weeks
(p < 0.001), and was maintained throughout the six
months' trial.

| Table Cumulative endoscopic relapse rates (%) |
|---------------------|---------------------|---------------------|---------------------|
| Weeks after randomisation | Total |   |     |
|                      | (mg) | 6 | 12 | 24 |   |     |
|                      | (no.) | (%) | (no.) | (%) | (no.) | (%) |   |     |
| Present trial*      |       |   |     |     |   |     |
| Cimetidine           | 400  | 12 | 63 | 13 | 68 | 14 | 74 | 19 | NS |
| Placebo              | 10   | 59 | 11 | 65 | 11 | 65 | 17 |     |     |
| Previous trial†     |       |   |     |     |   |     |
| Cimetidine           | 800  | 2 | 10 | 4 | 19 | 5 | 24 | 21 | <0.0005 |
| Placebo              | 16 | 66 | 21 | 87 | 21 | 87 | 24 |     |     |

* After six months' maintenance treatment with cimetidine 800 mg at bedtime.
† No previous maintenance treatment.
Comparison of two trials for placebo relapse rates

The Figure shows the cumulative relapse rates on placebo during the double-blind part of both our present and previous trials. To aid the comparison, the cumulative relapse rate in the present trial includes relapses that occurred during the initial open part of the trial during treatment with cimetidine 800 mg at bedtime, so that the relapse rates are different from those quoted in the Table, in which no account is taken of relapse rates in the first six months. In those patients who had received cimetidine 800 mg maintenance treatment at bedtime for six months, the cumulative relapse rate was 72% at six weeks and 76% at 12 and 24 weeks. In our previous study, in patients with no previous maintenance treatment, the cumulative relapse rates were 66% at six weeks and 87% at 12 and 24 weeks (NS).

Symptoms

In the cimetidine-treated group the average number of days of pain per patient per week was 1.0 ± 0.2 over the first six weeks, compared with 2.0 ± 0.1 per patient per week in the placebo group (p > 0.005). There was no significant difference in night time pain and antacid consumption between the two groups. Seven of 11 placebo-treated patients who relapsed endoscopically during the trial but only four of the 14 cimetidine-treated patients had symptoms severe enough to require withdrawal from the trial.

Discussion

Our findings show that the pattern of endoscopic relapse on placebo after six months' bedtime cimetidine in a dose of 800 mg is similar to that obtained after only six weeks' treatment with cimetidine (Figure). This clearly demonstrates that maintenance treatment with cimetidine given at bedtime for a period of six months does not alter the subsequent natural history of duodenal ulcer once cimetidine is stopped. Endoscopy provides the only objective method of assessing relapse rate, and in both studies it was carried out on a double-blind basis. The present findings concur with those11-13 based on symptomatic relapse rate in confirming the widespread clinical impression that, once cimetidine maintenance treatment is stopped, then the underlying natural history of the duodenal ulcer reasserts itself; but they do not provide any evidence that the risk of relapse is increased by cimetidine treatment.

Our failure to find any significant reduction in endoscopic relapse rate during maintenance treatment in the conventional dose of 400 mg at bedtime contrasts with our earlier findings using the higher dose of 800 mg at bedtime, despite the similar placebo results in both trials. It also contrasts with other reported trials5-9 using 400 mg at bedtime, but these other trials have been mainly based on symptomatic relapse rates, subsequently confirmed endoscopically. Furthermore, we found a significant reduction in the overall frequency of daytime pain in the cimetidine-treated patients compared with the placebo-treated patients, despite the absence of any reduction in the endoscopic relapse rate in those treated with cimetidine 400 mg at bedtime. These findings raise the possibility that the reported effect of cimetidine 400 mg at bedtime in reducing ulcer relapse in other trials is mainly an antacid effect, whereas the effect of cimetidine 800 mg at bedtime is due to a real reduction in ulcer relapse rate.

A double-blind comparison between 400 and 800 mg cimetidine given at bedtime is needed in the same group of patients before it can be concluded that there is a definite difference in the endoscopic relapse rate. If no significant difference were found, this would suggest that the reduced efficacy of cimetidine 400 mg in the present study is due to some form of tolerance to cimetidine developing during the six months' pretreatment at the higher dose.
If future trials confirm that the higher dose of 800 mg at bedtime is more effective in preventing endoscopic relapse, what is the explanation? We have previously reported that doses of 400 mg and 800 mg cimetidine at bedtime inhibit nocturnal acid secretion to the same degree. On the other hand, there was a difference between the doses in terms of intragastric pH, the higher dose maintaining intragastric pH close to neutrality throughout the night, whereas the intragastric pH escaped from control on the lower dose of 400 mg during the latter part of the night and fell to an average value of approximately three, possibly due to a fall in blood cimetidine levels. Thus, duodenal ulcer relapse may depend on the pH of the fluid entering the duodenal bulb rather than on the total amount of acid secreted by the stomach during the night.

References
Bedtime cimetidine maintenance treatment: optimum dose and effect on subsequent natural history of duodenal ulcer.

W J Fitzpatrick, W S Blackwood and T C Northfield

doi: 10.1136/gut.23.3.239

Updated information and services can be found at:
_http://gut.bmj.com/content/23/3/239_

_These include:_

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
_Stomach and duodenum_ (1689)

Notes

To request permissions go to:
_http://group.bmj.com/group/rights-licensing/permissions_

To order reprints go to:
_http://journals.bmj.com/cgi/reprintform_

To subscribe to BMJ go to:
_http://group.bmj.com/subscribe/._